ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Taisho Pharmaceutical Holdings Co., Ltd.

Business Summary

Taisho Pharmaceutical Holdings Co. Ltd. engages in the management of its group companies which are engaged in the manufacture and sale of over-the-counter (OTC) drugs, food, and miscellaneous goods. It operates through the Self-Medication and Prescription segments. The Self-Medication segment conducts research and development (R&D), manufacture, and sale of OTC drugs, quasi-drugs, food, and general medical and hygiene supplies; and deals with the lease of real estate properties and management of hotels. The Prescription segment handles R&D, manufacture, and sale of ethical drugs. The company was founded on October 3, 2011 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2021 JPYUSD
Revenue282,037M2,659.28M
Gross Profit175,987M1,659.35M
Operating income19,966M188.25M
Income before tax22,976M216.63M
Net income13,316M125.55M
EBITDA42,007M396.07M
Diluted EPS166.631.57
Dividends Per Share1000.94
Total Assets876,923M7,935.95M
Total liabilities117,853M1,066.54M
Total equity729,506M6,601.86M
Operating cash flow42,026M396.25M
Currency in JPYCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 279,750M 280,138M 261,369M 288,720M 282,037M
Gross Profit 178,225M 182,984M 170,163M 180,334M 175,987M
Operating income 31,965M 36,977M 31,212M 21,138M 19,966M
Income before tax 41,956M 48,070M 64,484M 29,775M 22,976M
Net income 28,781M 31,679M 48,594M 20,173M 13,316M
EBITDA 43,635M 48,357M 42,502M 38,158M 42,007M
Diluted EPS 359.93 396.20 608.22 252.44 166.63
Dividends Per Share 110 110 110 110 100
Total Assets 771,222M 799,616M 821,782M 864,974M 876,923M
Total liabilities 106,132M 108,296M 97,643M 124,482M 117,853M
Total equity 649,938M 675,231M 712,972M 710,148M 729,506M
Operating cash flow 40,066M 39,852M 19,222M 41,992M 42,026M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 2,583.40M 2,527.58M 2,356.91M 2,655.48M 2,659.28M
Gross Profit 1,645.85M 1,650.99M 1,534.45M 1,658.61M 1,659.35M
Operating income 295.18M 333.62M 281.45M 194.41M 188.25M
Income before tax 387.45M 433.71M 581.48M 273.85M 216.63M
Net income 265.78M 285.82M 438.19M 185.54M 125.55M
EBITDA 402.95M 436.30M 383.26M 350.95M 396.07M
Diluted EPS 3.32 3.57 5.48 2.32 1.57
Dividends Per Share 1.01 0.99 0.99 1.01 0.94
Total Assets 6,921.13M 7,518.71M 7,424.51M 8,012.35M 7,935.95M
Total liabilities 952.45M 1,018.29M 882.17M 1,153.09M 1,066.54M
Total equity 5,832.70M 6,349.13M 6,441.45M 6,578.18M 6,601.86M
Operating cash flow 369.99M 359.56M 173.33M 386.21M 396.25M

Valuation Measures

Mar 2021
PER42.79
ROA1.52%
ROE1.84%
Operating margin7.07%
Profit margin4.72%

Key executives

  • President & Representative Director: Akira Uehara
  • Manager-Financial Affairs: Tsuyoshi Ishiguro
  • Director, Head-Audit & IT Planning: Ken Uehara
  • Director & Vice President: Shigeru Uehara
  • Director & Head-Quality Assurance: Katsuichi Ohsawa

Shareholders

  • The Uehara Memorial Foundation (17.6%)
  • UEHARA SHOJI (9.0%)
  • Taisho Pharmaceutical Holdings Co., Ltd. (6.1%)
  • Sumitomo Mitsui Financial Group, Inc. (5.4%)
  • Uehara Museum Foundation (4.5%)
  • Mitsubishi UFJ Financial Group, Inc. (4.2%)
  • UEHARA AKIRA (2.5%)
  • Kajima Corp. (1.9%)
  • Sumitomo Chemical Pension Fund (1.7%)
  • Nomura Asset Management Co., Ltd. (1.7%)

Contact Details

Related Companies

  • Taisho Pharma Co., Ltd
  • MEJIRO KOSAN Co., Ltd.
  • Kosei SA de CV
  • DHG Pharmaceutical Joint Stock Company
  • Tokuhon Corp.
  • Biofermin Pharmaceutical Co., Ltd.
  • Taisho Pharmaceutical Co., Ltd.

Competitors

  • Monster Beverage Corporation
  • LT Group, Inc.
Last Updated on 26 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more